Unassociated Document

0001144204-05-007339.txt : 20120626 0001144204-05-007339.hdr.sgml : 20120626 20050311145238 ACCESSION NUMBER: 0001144204-05-007339 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20050311 DATE AS OF CHANGE: 20050311 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TANNEBAUM LLC CENTRAL INDEX KEY: 0001203994 IRS NUMBER: 030400032 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A MAIL ADDRESS: STREET 1: 875 N. MICHIGAN AVENUE STREET 2: SUITE 2930 CITY: CHICAGO STATE: IL ZIP: 60611 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: IMCOR PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000761237 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 621742885 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-53647 FILM NUMBER: 05675184 BUSINESS ADDRESS: STREET 1: 6175 LUSK BOULEVARD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858 410-5601 MAIL ADDRESS: STREET 1: 6175 LUSK BLVD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: PHOTOGEN TECHNOLOGIES INC DATE OF NAME CHANGE: 19970529 SC 13D/A 1 v014210.htm Unassociated Document

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Information to be included in Statements filed pursuant to § 240.13d-1(a)

and Amendments thereto filed pursuant to § 240.13d-2(a)

Under the Securities Exchange Act of 1934

(Amendment No. 4)*

IMCOR Pharmaceutical Co.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

71932A-30-9

(CUSIP Number)

Tannebaum, LLC

875 North Michigan Avenue, Suite 2930, Chicago, Illinois 60611 (312/397-2626)

(Name, Address and Telephone Number of Person

Authorized to Receive Notices and Communications)

February 16, 2005

(Date of Event which Requires Filing of this Statement)

If the filling person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box / /.

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a proper cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 71932A-30-9


(1)	Names of Reporting Persons.
	S.S. or I.R.S. Identification		Tannebaum, LLC
	Nos. of Above Persons

(2)	Check the Appropriate Box if a		(a) \|X\|
	Member of a Group (See Instructions)		(b) \|_\|

(3)	SEC Use Only

(4)	Source of Funds (See Instructions)		OO

(5)	Check if Disclosure of Legal Proceedings
	is Required Pursuant to Items 2(d) or 2(e)

(6)	Citizenship or Place of Organization		Delaware

Number of Shares Beneficially		(7)	Sole Voting Power 2,344,957^(A)
Owned by Each Reporting Person
With		(8)	Shared Voting Power 0

		(9)	Sole Dispositive Power 2,344,957^(A)

		(10)	Shared Dispositive Power 0

(11)	Aggregate Amount Beneficially Owned
	By Each Reporting Person		2,344,957^(A)

(12)	Check if the Aggregate Amount in Row (11)
	Excludes Certain Shares (See Instructions)

(13)	Percent of Class Represented by Amount in Row (11)		2.9%

(14)	Type of Reporting Person (See Instructions)		OO

(A) The reporting person was a party to a Voting, Drag-Along and Right of First Refusal Agreement (the “Voting Agreement”) described in Item 4, below. The Voting Agreement was unanimously terminated by the parties thereto. The termination agreement was executed by the final signatory on February 16, 2005 with the termination effective as of February 1, 2005.

Item 1.

SECURITY AND ISSUER.

This Schedule 13D relates to common stock ("Common Stock") of IMCOR Pharmaceutical Co., a Nevada corporation (the "Issuer"). The principal executive offices of the Issuer are located at 6175 Lusk Boulevard, San Diego, CA 92121.

Item 2.

IDENTITY AND BACKGROUND.

Set forth below is the following information with respect to the filing on this Schedule 13D: (a) name; (b) business address; (c) principal occupation and name, business and address of employer; (d) information concerning criminal convictions during the last five years; (e) information concerning civil or administrative proceedings under state or federal securities laws during the past five years with respect to any state or federal securities laws; and (f) citizenship.

Tannebaum, LLC

875 North Michigan Avenue, Suite 2930, Chicago, IL 60611

not applicable

No criminal convictions (1)

No adverse civil judgments for violations of securities laws (1)

not applicable

(1) During the last five years, neither the filing person nor any person described in General Instruction C to Schedule 13D with respect to a filing person that is an entity has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors), nor have such persons been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction that resulted in his becoming subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

Item 3.

SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION.

On March 6, 2002, Tannebaum, LLC received shares of the Issuer from the Theodore Tannebaum Trust, U/A/D March 5, 1990, most recently restated in its entirety on February 20, 1999, and further amended on January 31, 2000, in exchange for the Trust’s membership interest in Tannebaum, LLC.

The purpose of Amendment No. 1 was to report the call options that were granted by Tannebaum, LLC to STRO, LLC and Tannebaum Ventures, LLC.

The purpose of Amendment No. 2 was to report the acquisition by Tannebaum, LLC of 2,314,815 shares of Common Stock of the Issuer at $1.08 per share (post-reverse split).

The purpose of Amendment No. 3 was to report that on May 19, 2003 Tannebaum, LLC transferred an aggregate of 999,088 shares of Common Stock to various individuals in exchange for STRO, LLC’s withdrawal as manager and a member of Tannebaum, LLC.

The purpose of this Amendment No. 4 is to report that the Voting Agreement, described in Item 4 below, has been terminated.

Item 4.

PURPOSE OF TRANSACTION.

The shares of Common Stock covered by this filing are being held by Tannebaum, LLC for investment purposes. The reporting person will continue to monitor and evaluate its investment in the Issuer in light of pertinent factors, including, without limitation, the following: (a) the Issuer’s business, operations, assets, financial condition and prospects, (b) market, general economic and other conditions, and (c) other investment opportunities available to the reporting person. In light of the foregoing factors, and the plans and requirements of the reporting person from time to time, including the plans described below, the reporting person may decide to (i) dispose of some or all of the shares of Common Stock that it beneficially owns, or (ii) acquire additional shares of Common Stock or other securities of the Issuer.

On October 16, 2002, Tannebaum, LLC signed a Call Agreement granting call options to STRO, LLC and Tannebaum Ventures, LLC to purchase all of Tannebaum, LLC’s shares of the Issuer.

On November 12, 2002, the Issuer split off its photodynamic therapy and laser device business to five founding shareholders in exchange for all of their Common Stock, which represented 52.9% of the Issuer's outstanding shares. Simultaneously with the split off transaction, The Issuer sold $9,000,000 of Common Stock to a group of venture capital funds led by Mi3 L.P. of Wellesley, MA and including Tannebaum, LLC and Oxford Bioscience Partners IV L.P. The financing agreements included a Voting Agreement pursuant to which (among other things) the reporting person agreed to maintain the Issuer’s Board of Directors at seven members and to vote to elect certain persons to the Board.

On May 19, 2003, Tannebaum, LLC transferred an aggregate of 999,088 shares of Common Stock to various individuals in exchange for STRO, LLC’s withdrawal as manager and member of Tannebaum, LLC.

The Voting Agreement was unanimously terminated by the parties thereto. On February 16, 2005, the termination agreement was executed by the final signatory with the termination effective as of February 1, 2005.

Except as described above, the reporting person has no current plans or proposals that relate to or would result in:

1.	The acquisition of additional securities of the Issuer, or the disposition of securities of the Issuer;

2.	An extraordinary corporate transaction, such as a merger, reorganization or liquidation, involving the Issuer or any of its subsidiaries;

3.	A sale or transfer of a material amount of assets of the Issuer or any of its subsidiaries;

4.	Any change in the present board of directors or management of the Issuer, including any plans or proposals to change the number or term of directors or to fill any existing vacancies on the board;

5.	Any material change in the present capitalization or dividend policy of the Issuer;

6.	Any other material change in the Issuer's business or corporate structure;

7.	Changes in the Issuer's charter, bylaws or instruments corresponding thereto or other actions which may impede the acquisition of control of the Issuer by any person;

8.	Causing a class of securities of the Issuer to be delisted from a national securities exchange or to cease to be authorized to be quoted in an inter-dealer quotation system of a registered national securities association;

9.	A class of equity securities of the Issuer becoming eligible for termination of registration pursuant to Section 12(g)(4) of the Exchange Act; or

10.	Any action similar to any of those enumerated above.

Item 5.

INTEREST IN SECURITIES OF THE ISSUER.

Name of Item or Person	Common Stock Beneficially Owned (4)	% of Class (1)	Voting Power
Tannebaum, LLC	2,344,957 (2)	2.9%	Sole (3)

(1) All percentages in this table are based, pursuant to Rule 13d-1(e) of the Securities Exchange Act of 1934, on the 80,065,300 shares of Common Stock of the Issuer outstanding as of November 26, 2004.

(2) Excludes shares of Common Stock owned by other persons that were subject to the Voting Agreement described in Item 4, above.

(3) Common Stock owned by the reporting person is no longer subject to the Voting Agreement described in Item 4, above.

(4) All share totals in this table are after a one for four reverse split of Issuer’s Common Stock which was consummated simultaneously with the financing transaction described in Item 4 above.

Item 6.

CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER.

The split off transaction, the financing transaction, the Voting Agreement and the related termination agreement, and the call agreement with the reporting person are described in Item 4, above. There are no other contracts, arrangements or understandings with Tannebaum, LLC made or entered into specifically with respect to holding, voting or disposing of the Common Stock of the Issuer.

Item 7.

MATERIAL TO BE FILED AS EXHIBITS.

The following exhibits are filed with this Schedule 13D:

Voting Agreement dated as of November 12, 2002 by and among Robert J. Weinstein, M.D. (individually and as Director of the Robert and Lois Weinstein Family Foundation, Inc. and as Trustee of the Robert and Lois Weinstein Joint Revocable Trust), Stuart Levine (individually and as Trustee of the Theodore Tannebaum Trust), Tannebaum LLC, Mi3 L.P., Oxford Bioscience and MRNA Fund II, L.P. (collectively, the “Stockholders”) (incorporated by reference to Schedule G to the Issuer’s DEFM 14A filing dated September 12, 2002).

2.	Call Agreement entered into as of October 16, 2002 by and among Tannebaum, LLC, STRO, LLC and Tannebaum Ventures, LLC (incorporated by reference to Exhibit A to the reporting person’s Schedule 13D/A filing dated January 7, 2003).

3.	The Voting, Drag-Along and Right of First Refusal Agreement Termination Approval by and among the Stockholders executed by the final signatory on February 16, 2005 with the termination effective as of February 1, 2005.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 8, 2005


	Tannebaum, LLC

	By:	Tannebaum Ventures, LLC as sole manager of reporting person

	By:	/s/ Louis D. Williams
		Louis D. Williams, as President

EX-99.1 2 v014210_ex99-1.htm Unassociated Document

Exhibit 99.1

THE VOTING, DRAG-ALONG AND RIGHT OF FIRST REFUSAL AGREEMENT

TERMINATION APPROVAL

This TERMINATION APPROVAL is entered into as of February 1, 2005.

(1)

On November 12, 2002, the “Venture Stockholders” (i.e., Oxford BioScience Partners IV L.P. (“Oxford”), Mi3 L.P. (“Mi3”) and MRNA Fund II L.P. (“MRNA”)) and the “Chicago Stockholders” (i.e., Robert J. Weinstein, M.D. (individually and as Director of the Robert and Lois Weinstein Family Foundation, Inc., the Trustee of the Robert and Lois Weinstein Joint Revocable Trust (“Weinstein”), Stuart Levine (individually and as Trustee of the Theodore Tannebaum Trust (“Levine”), and the Tannebaum, LLC (“TLLC”)) of IMCOR Pharmaceutical Co. (f/k/a “Photogen Technologies, Inc., the “Company”) entered into a Voting, Drag-Along and Right of First Refusal Agreement (the “Voting Agreement”).

(2)

Section 5.10 of the Voting Agreement provides that it may be modified or amended in any respect upon the written approval of the holders of 90% of the shares held by the parties thereto, and as so modified or amended, the Voting Agreement shall continue to bind all Stockholders whether they consented to such modification or amendment.

(3)	As of November 26, 2004, the Venture and Chicago Stockholders to the Voting Agreement beneficially owned the following shares of the Company:

Oxford*			46,484,770
MI3			2,904,098
Weinstein			1,314,663
Levine			1,277,386
TLLC			2,344,957
Total			54,325,874
*Includes MRNA

(4)

The parties to the Voting Agreement (or the beneficial holders of at least 90% of the stockholders who are parties to the Voting Agreement) no longer desire to maintain or continue the Voting Agreement and therefore upon their written approval set for the below, elect to terminate the Voting Agreement.

[Signature Page Follows]

IN WITNESS WHEREOF, the parties hereto have executed their written approval to the Termination of the Voting Agreement as of the date first written above. Termination of the Voting Agreement as of the date first written above.

	/s/ Robert J. Weinstein Robert J. Weinstein, M.D., individually and as Director of the Robert and Lois Weinstein Family Foundation, Inc., and as Trustee of the Robert and Lois Weinstein Joint Revocable Trust

	/s/ Stuart Levine Stuart Levine, individually and as General Partner of SL Investment Enterprises, L.P. and as President of the Stuart and Sherri Levine Family Foundation, Inc.

	Tannebaum, LLC
		By: Tannebaum Ventures, LLC, Its Sole Manager

		By: /s/ Louis Williams
		Louis D. Williams, Its Sole Manager

	Mi3 L.P.
		By: Mi3 Services L.L.C., Its General Partner

		By: /s/ William McPhee
		William D. McPhee, President

	Oxford Bioscience Partners IV L.P.
		By: OBP Management IV L.P.

		By: /s/ Jonathan Fleming
		Jonathan J. Fleming, General Partner